{"id":917500,"date":"2025-12-08T16:05:00","date_gmt":"2025-12-08T21:05:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-inspire-medical-systems-inc-nyse-insp-should-contact-wolf-haldenstein-immediately-2\/"},"modified":"2025-12-08T16:05:00","modified_gmt":"2025-12-08T21:05:00","slug":"shareholders-who-lost-money-in-shares-of-inspire-medical-systems-inc-nyse-insp-should-contact-wolf-haldenstein-immediately-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-inspire-medical-systems-inc-nyse-insp-should-contact-wolf-haldenstein-immediately-2\/","title":{"rendered":"Shareholders who lost money in shares of Inspire Medical Systems, Inc. (NYSE: INSP) Should Contact Wolf Haldenstein Immediately"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Lead Plaintiff Deadline is January 5, 2026<\/span><\/b>\n <\/p>\n

\n
\n NEW YORK<\/span>
\n <\/span>, Dec. 8, 2025<\/span><\/span> \/PRNewswire\/ — Wolf Haldenstein Adler Freeman<\/span> & Herz LLP<\/a>\u00a0informs investors in Inspire Medical Systems, Inc. (NYSE: INSP)<\/b>\u00a0(“Inspire”)<\/b>\u00a0that a securities class action has been filed on behalf of all those who purchased shares between August 6, 2024<\/span> and August 4, 2025<\/span><\/b> (the “Class Period”). Investors have until January 5, 2026<\/span><\/b>\u00a0to seek appointment as lead plaintiff.<\/b><\/p>\n

\n

\n
\n \"(PRNewsfoto\/Wolf
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n
\n PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION<\/a>
\n <\/b>\n <\/p>\n

\n Allegations<\/b>\n <\/p>\n

The complaint filed alleges<\/span>Inspire Medical Systems, Inc.<\/b>, and certain company officers or directors engaged in securities fraud<\/span><\/b> or other unlawful business practices<\/b>. The lawsuit centers on whether the company misled investors about the launch and performance of its new Inspire V sleep apnea device<\/b>.<\/p>\n

\n Background and Disclosure<\/b>\n <\/p>\n

On August 4, 2025<\/span><\/b>, Inspire disclosed several setbacks affecting the rollout of Inspire V:<\/p>\n

    \n
  1. \n Training and Onboarding Delays:<\/b>
    \n
    Many centers failed to complete necessary training, contracting, and onboarding steps before purchasing or implanting the device.<\/li>\n
  2. \n Billing and Medicare Reimbursement Issues:<\/b>
    \n
    Although Inspire V’s CPT code was approved for Medicare, billing software updates did not take effect until July 1<\/span><\/b>, delaying claims and reimbursement processing.
    \u2192 Many centers continued using the older Inspire IV<\/b> device.<\/li>\n
  3. \n Excess Inventory Problems:<\/b>
    \n
    Surplus inventory further hampered the Inspire V rollout.<\/li>\n<\/ol>\n

    Because of these issues, Inspire slashed its earnings guidance<\/b> by more than 80%<\/b> \u2014 from $2<\/span>.20\u2013$2.30 per share<\/b> down to $0<\/span>.40\u2013$0.50 per share<\/b>.<\/p>\n

    \n Reaction<\/b>\n <\/p>\n

    On this news, the price of Inspire’s common stock declined more than 32%, from a close of $129.95<\/span> per share on August 4, 2025<\/span>, to close at $87.91<\/span> per share on August 5, 2025<\/span> wiping out $1.2 billion<\/span> in market capitalization in a single day of trading. From the Company’s Class Period stock price closing high of $216.71<\/span> per share on September 23, 2024<\/span>, Inspire Medical’s stock price dropped an astonishing $127.00<\/span> per share, or nearly 60%, erasing billions of dollars from the Company’s market capitalization.<\/p>\n

    \n Lead Plaintiff Deadline<\/b>\n <\/p>\n

    Investors who suffered losses have until January 5, 2026<\/span><\/b>, to seek appointment as lead plaintiff.<\/p>\n

    \n Why\u00a0<\/b>
    \n
    \n
    \n Wolf Haldenstein Adler Freeman<\/span> & Herz LLP?<\/a>
    \n <\/b>
    \n :<\/b>\n <\/p>\n

    This illustrious firm<\/a>, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements.\u00a0The law firm\u00a0<\/a>brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.<\/p>\n

    We encourage all investors who have been affected or have information that will assist in our investigation, to contact\u00a0Wolf Haldenstein Adler Freeman<\/span> & Herz LLP<\/a>.<\/p>\n

    \n Contact:<\/b>\n <\/p>\n